Zacks Research Analysts Raise Earnings Estimates for RDY

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Equities researchers at Zacks Research raised their Q2 2027 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a research note issued to investors on Wednesday, October 16th. Zacks Research analyst R. Department now forecasts that the company will earn $0.78 per share for the quarter, up from their previous forecast of $0.77. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $4.11 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ FY2027 earnings at $3.13 EPS.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Saturday, July 27th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.10). Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%. The business had revenue of $919.80 million during the quarter, compared to analysts’ expectations of $861.68 million.

Separately, Barclays upped their target price on shares of Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY opened at $79.67 on Friday. The company has a market capitalization of $13.30 billion, a price-to-earnings ratio of 19.77, a price-to-earnings-growth ratio of 1.73 and a beta of 0.55. Dr. Reddy’s Laboratories has a 52-week low of $63.72 and a 52-week high of $84.46. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average price of $80.38 and a 200 day moving average price of $76.35.

Institutional Trading of Dr. Reddy’s Laboratories

Large investors have recently made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund increased its position in Dr. Reddy’s Laboratories by 318.0% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock worth $28,411,000 after buying an additional 283,700 shares during the period. Millennium Management LLC increased its holdings in shares of Dr. Reddy’s Laboratories by 61.4% in the 2nd quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock valued at $25,333,000 after acquiring an additional 126,472 shares during the period. Dimensional Fund Advisors LP raised its position in Dr. Reddy’s Laboratories by 12.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock valued at $76,455,000 after purchasing an additional 114,294 shares during the last quarter. Jane Street Group LLC boosted its stake in Dr. Reddy’s Laboratories by 2,197.8% during the 1st quarter. Jane Street Group LLC now owns 113,168 shares of the company’s stock worth $8,301,000 after purchasing an additional 108,243 shares during the period. Finally, National Bank of Canada FI grew its position in Dr. Reddy’s Laboratories by 81.6% during the 2nd quarter. National Bank of Canada FI now owns 184,120 shares of the company’s stock worth $13,884,000 after purchasing an additional 82,724 shares during the last quarter. 14.02% of the stock is owned by institutional investors and hedge funds.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.